Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
pharmaceutical drug
|
| gptkbp:activeDuring |
tenofovir alafenamide
|
| gptkbp:clinicalTrials |
Phase 3
|
| gptkbp:contraindication |
hypersensitivity to tenofovir alafenamide
|
| gptkbp:date |
2016-11-10
|
| gptkbp:dosageForm |
tablet
|
| gptkbp:drugInterdiction |
true
antiviral |
| https://www.w3.org/2000/01/rdf-schema#label |
Vemlidy
|
| gptkbp:manufacturer |
gptkb:Gilead_Sciences
|
| gptkbp:marketedAs |
gptkb:European_Union
gptkb:United_States |
| gptkbp:packaging |
bottle of 30 tablets
|
| gptkbp:patentExpiration |
2028-07-27
|
| gptkbp:route |
oral
|
| gptkbp:sideEffect |
headache
nausea diarrhea |
| gptkbp:skills |
25 mg
|
| gptkbp:storage |
store at room temperature
|
| gptkbp:usedFor |
treatment of chronic hepatitis B
|